biOasis Initiates Transcend Vector Program Targeting Treatments for CNS Symptoms of Lysosomal Storage Disorders

Published: May 11, 2011

VANCOUVER, British Columbia, May 11, 2011 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) announced today the initiation of its first Transcend therapeutic development program directed towards developing treatments for the neurological effects of lysosomal storage disorders ("LSD"). This strategic decision is based on recently announced results from the National Research Council of Canada demonstrating that intravenously administered Transcend is delivered into brain cell lysosomes and data from the company showing that brain lysosomal enzyme activity can be restored and enhanced in animals when linked to Transcend. These properties of Transcend offer the possibility of enhancing the brain delivery of specific lysosomal enzymes as replacement therapies to address the neurological manifestations of lysosomal storage diseases.

Back to news